U.S. Gastrointestinal Point of Care Testing Market Size, Share, and Growth Forecast 2026 - 2033

The U.S. gastrointestinal point of care testing market size is expected to be valued at US$ 1,022.3 million in 2026 and projected to reach US$ 2,043.4 million by 2033, growing at a CAGR of 10.4% between 2026 and 2033.

The growing prevalence of gastrointestinal disorders such as infections, inflammatory bowel disease (IBD), and colorectal cancer requires rapid, accurate, and accessible diagnostic solutions. Continuous advancements in molecular diagnostics and immunoassay technologies have significantly enhanced the speed, accuracy, and ease of use of POCT devices, supporting early disease detection and timely clinical decision-making. The growing shift toward decentralized, patient-centric healthcare has further accelerated POCT adoption in hospitals, clinics, emergency settings, and home care.

In addition, supportive government initiatives are strengthening market growth, with organizations such as the CDC emphasizing the burden of digestive diseases and the FDA encouraging the development and availability of innovative point-of-care and home-based diagnostic technologies.

Drivers - Rising GI Disease Burden and Demand for Rapid Diagnosis Fuels Growth

One of the key drivers of the U.S. gastrointestinal point-of-care testing market is the rising prevalence of gastrointestinal diseases and infections that require rapid diagnosis and timely treatment. According to the Centers for Disease Control and Prevention (CDC), there are approximately 179 million cases of acute gastroenteritis in the U.S. each year. Norovirus alone accounts for an estimated 19 to 21 million illnesses, 109,000 hospitalizations, and nearly 900 deaths annually.

Additionally, bacterial infections such as Clostridioides difficile cause almost 223,900 hospitalizations and 12,800 deaths in the U.S. each year. Point-of-care tests help healthcare providers diagnose these conditions on-site, reducing the time between symptom onset and treatment. This is especially important in emergency departments, urgent care clinics, and long-term care facilities where timely diagnosis limits the spread of infection and improves outcomes. The growing trend toward decentralized healthcare, where patients receive care outside traditional settings increases the demand for portable and easy-to-use diagnostic tests. As the awareness of colorectal cancer screening increases through fecal immunochemical tests (FIT), the clinical demand for POCT procedures underscores the significance.

Restraints - Accuracy Concerns and Regulatory Hurdles

A key restraint in the U.S. gastrointestinal point-of-care testing market is the limited accuracy in the sensitivity and specificity of certain rapid diagnostic tests. While POCT offers convenience and speed, some tests may produce false positives or negatives, leading to misdiagnosis or delayed treatment. This can undermine clinician confidence and reduce adoption in critical care settings. Moreover, despite advancements, not all POCT devices are capable of detecting a wide range of pathogens simultaneously, limiting their use in complex gastrointestinal cases.

Regulatory challenges also act as a barrier, as approval processes for new diagnostic tools can be lengthy and complex. Reimbursement policies for POCT are not uniform across payers, and inadequate coverage may deter healthcare providers from integrating these tools into routine care. Additionally, initial costs of acquiring advanced POCT platforms can be high, especially for smaller practices and rural clinics, further limits market penetration.

Market Opportunities

Technological Innovation and Preventive Care Trends Create Strong Growth Opportunities

The U.S. gastrointestinal point-of-care testing market presents strong growth opportunities through advancements in diagnostic technology and the increasing shift toward decentralized healthcare. One major opportunity lies in developing smartphone-compatible and digital POCT solutions, which enhance accessibility and allow patients to conduct tests at home with real-time results shared with healthcare providers. The growing popularity of telehealth services also creates a favorable environment for integrating POCT into remote care. Additionally, the emphasis on preventive healthcare and early disease detection supports the demand for non-invasive, easy-to-use tests such as fecal immunochemical tests (FIT) for colorectal cancer screening.

Expanding awareness campaigns and government-backed screening programs further drive interest in early diagnosis. Moreover, underserved rural and community health settings offer untapped potential for point-of-care diagnostic expansion, as these areas often lack access to centralized laboratories. Together, these trends highlight the market's potential for innovation and wider adoption across diverse healthcare environments.

Product Analysis

In the U.S., gastrointestinal point-of-care testing assay kits are expected to lead the by a 41% market share in 2026, primarily due to their accuracy, reliability, and broad application in detecting various GI conditions such as H. pylori, Clostridioides difficile, and Salmonella. These kits, which include rapid immunoassays and molecular diagnostic tools are widely used across hospitals, clinics, and even home settings due to their convenience and ability to deliver quick results.

Additionally, dipsticks represent the fastest growing segment, particularly for fecal occult blood testing (FOBT), a common non-invasive method for colorectal cancer screening. Their affordability and simplicity make them accessible in primary care and community health environments, although technological limitations have slowed their growth compared to newer formats.

Furthermore, cassette-based tests, often built on lateral flow assay technology, are rapidly gaining momentum as the second fastest-growing segment. Their user-friendly design and minimal sample preparation requirements make them ideal for urgent care, physician offices, and telemedicine kits.

Indication Analysis

Gastrointestinal point-of-care testing in the U.S. is primarily driven by the need to quickly identify and manage infectious diseases. Bacterial infections, such as those caused by Clostridioides difficile, Salmonella, and Helicobacter pylori, account for a large share of diagnostic demand due to their severity and potential complications. Viral infections, especially those caused by Norovirus and Rotavirus, are widespread and highly contagious, contributing to millions of cases each year. These infections often lead to outbreaks in schools, long-term care facilities, and other communal environments, highlighting the necessity of fast, on-site testing.

Parasitic infections, though less prevalent, remain important for specific populations, including travelers and immunocompromised individuals. Pathogens such as Giardia lamblia and Cryptosporidium require targeted diagnostics, particularly in clinical and public health settings. Additionally, colorectal cancer screening using fecal immunochemical tests (FIT) is gaining traction for early detection. These various indications underscore the critical role of accessible diagnostics in both treatment and prevention.

End-user Analysis

Hospitals and Clinics lead the end-user category, holding approximately 34% share in 2025. These facilities handle the majority of gastrointestinal diagnostic testing volume nationwide. The Centers for Disease Control and Prevention (CDC) coordinates infection control protocols primarily through hospital-based testing programs. Hospitals require rapid, on-site testing to guide immediate treatment and isolation decisions. This urgency sustains consistent, high-volume testing demand within hospital and clinic settings.

Physicians also prefer conducting point-of-care tests during routine patient visits for immediate results. This convenience reinforces hospitals and clinics' leading position within the broader end-user category. Home Care Settings, meanwhile, are growing at the fastest pace through 2033. Rising preference for convenient, at-home testing supports this accelerating segment growth trend. Diagnostic Laboratories and Urgent Care Centers also continue contributing steady, complementary testing volumes.

Southeast U.S. Gastrointestinal Point of Care Testing Market Trends and Insights

Southeast U.S. leads the gastrointestinal point of care testing market, holding around 30% share in 2026. Large aging populations across Florida and neighboring states drive strong regional demand. The U.S. Census Bureau reports significant elderly population concentration across this region. Growing colorectal cancer screening participation further reinforces this leading regional position. States like Florida and Georgia continue attracting large retiree populations requiring regular screening.

Southwest U.S. Gastrointestinal Point of Care Testing Market Trends and Insights

Southwest U.S. is the fastest-growing gastrointestinal point of care testing market in the forecast period. Rising population growth across Arizona and Texas drives strong regional demand growth. The U.S. Census Bureau reports rapid population growth across this region. Expanding urgent care and home care testing infrastructure further supports this accelerating regional growth trend. Growing healthcare investment across fast-growing metro areas further reinforces this positive outlook.

West U.S. Gastrointestinal Point of Care Testing Market Trends and Insights

West U.S. represents a large, technology-forward gastrointestinal point of care testing market. Strong healthcare infrastructure across California supports steady regional demand growth. The U.S. Census Bureau reports a substantial population base across this region. Growing adoption of home-based diagnostic testing further supports this region's steady expansion nationwide. Technology-forward healthcare systems across the region continue piloting new digital screening programs.

The U.S. gastrointestinal point of care testing (POCT) market is moderately competitive, with a mix of established diagnostic companies and emerging players. Leading firms such as Abbott Laboratories, QuidelOrtho Corporation, Bio-Rad Laboratories, and Thermo Fisher Scientific dominate due to their extensive product portfolios, technological innovation, and strong distribution networks. These companies focus on developing rapid, accurate, and easy-to-use diagnostic kits and devices that cater to the growing demand in clinical and home settings.

Mid-sized players and startups are also entering space, offering specialized tests and niche technologies such as microfluidics and smartphone-enabled diagnostics. Strategic partnerships, acquisitions, and continuous R&D investment are common strategies used to gain a competitive edge. Additionally, companies are aligning their offerings with regulatory guidelines to ensure faster approvals and broader market access. As demand for decentralized healthcare grows, the competition is expected to intensify with innovation and cost-effectiveness becoming key differentiators in the market.

Key Developments:

• In June 2026, bioMérieux submitted the BIOFIRE® FILMARRAY® Gastrointestinal (GI) 1.1 Panel and GI 1.1 Panel Mid to the U.S. FDA for 510(k) review, expanding rapid syndromic gastrointestinal pathogen testing capabilities.
• In March 2026, QIAGEN received U.S. FDA clearance for its QIAstat-Dx® Gastrointestinal Panels on the fully automated QIAstat-Dx Rise system, enabling high-throughput syndromic testing of GI pathogens with enhanced laboratory workflow efficiency.
• In August 2024, MP Biomedicals launched a new line of in vitro diagnostic kits utilizing immunochromatographic technology to identify gastrointestinal pathogens. These tests are specifically designed to detect Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139.
• In February 2024, Reese Pharmaceutical launched ColoTest, an FDA-approved over-the-counter fecal immunochemical test (FIT) for at-home use. The test is designed to detect hidden blood in the stool, which can be an early warning sign of colorectal cancer and other gastrointestinal conditions.